Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
14c}-GSK1349572 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | \[14C\]-GSK1349572 administered as a single oral dose |
| Name | Type | Description |
|---|---|---|
| [14c}-GSK1349572 | DRUG | HIV-Integrase inhibitor labelled with a carbon 14 marker |
Inclusion Criteria: * Healthy as determined by a responsible physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring. * Male subjects between 30 and 55 years of age. * Male subjects must agree to use one of the contraception ...
14c}-GSK1349572 is an investigational small molecule developed by GSK plc. It has been studied in a Phase 1 mass balance trial in healthy male volunteers. The specific therapeutic indication for this compound has not been disclosed.
14c}-GSK1349572 is being developed by GSK plc, which trades under the ticker GSK. GSK sponsored the Phase 1 mass balance study of the compound conducted in the United States.
14c}-GSK1349572 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The compound has not been approved by the FDA and remains investigational.
14c}-GSK1349572 has been evaluated in one completed Phase 1 trial, NCT00828763, titled the GSK1349572 Mass Balance Study. The trial enrolled 6 healthy male volunteers aged 30 years and older in the United States and was uncontrolled.
Yes, 14c}-GSK1349572 is also known as GSK1349572. Both names refer to the same investigational small molecule developed by GSK plc. The trial registered under NCT00828763 uses the GSK1349572 name.